Saamna, 29 January 2021:

Sanjiv Navangul, MD and CEO of Bharat Serums and Vaccines Ltd., said that Bharat Serum and Vaccines (BSV) is conducting the phase III clinical study of Ulinastatin for ARDS patients. BSV has also initiated a research project to co-develop an equine polyclonal antibody against COVID-19.

Read more:

About BSV

BSV has been a pioneer in the development of blood components and therapeutic antibody products for infectious and non-infectious diseases. For over four decades, BSVL has focused on utilizing its scientific resources to develop several biological, biotechnology and pharmaceutical products to treat various types of diseases, contributing to preserve, protect and enhance the quality of life. We aim to be a leading biopharmaceutical company driven by people & science to set benchmarks in patient outcomes in Women’s Health, Critical Care & Emergency Medicine.

For more information, please contact:

Irawati Gowariker, BSV, Irawati.gowariker@bsvgroup.com